Skip to main content

Advertisement

SpringerLink
Log in

Downstaging to non-invasive urothelial carcinoma is associated with improved outcome following radical cystectomy for patients with cT2 disease

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Introduction

Pathologic stage is a critically important prognostic factor after radical cystectomy (RC) that is used to guide the use of secondary therapies. However, the risk of disease recurrence, for patients clinically diagnosed with muscle-invasive tumors who are found not to have muscle-invasive disease at RC are poorly defined. Therefore, we reviewed the long-term outcomes in patients who were downstaged to non-invasive urothelial carcinoma at time of RC.

Methods

We identified 1,177 consecutive patients with muscle-invasive urothelial carcinoma of the bladder who underwent radical cystectomy at our institution between 1980 and 1999 without neoadjuvant therapy. Postoperative disease recurrence and survival were estimated using the Kaplan–Meier method and compared using the log rank test. Cox proportional hazard regression models were used to analyze the impact of pathologic stage on survival.

Results

Pathologic downstaging to non-muscle invasive disease was identified in 538 (45.7 %) patients. The 10-year cancer-specific survival was 84.1, 77.4, 71.1 and 58.5 % for those with pT0, pTis, pT1 and pT2 tumors, respectively. On multivariate analysis, the risk of cancer-specific mortality was significantly decreased for patients with non-muscle invasive disease than those with organ-confined muscle invasion (RR−0.39; p = 0.002). There was no difference in disease-specific mortality among patients who had non-invasive (pT0, pTa, or pTis) disease (p = 0.19).

Conclusions

Downstaging from clinical muscle-invasive bladder cancer to non-muscle invasive disease at RC is associated with a significant reduction in cancer-specific mortality. However, even patients with residual non-muscle invasive disease may suffer disease recurrence and require continued surveillance after surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Xu J et al (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277

    Article  PubMed  Google Scholar 

  2. Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19:666

    PubMed  CAS  Google Scholar 

  3. Hollenbeck BK, Miller DC, Dunn RL et al (2005) The effects of stage divergence on survival after radical cystectomy for urothelial cancer. Urol Oncol 23:77

    Article  PubMed  Google Scholar 

  4. Shariat SF, Palapattu GS, Karakiewicz PI et al (2007) Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 51:137

    Article  PubMed  Google Scholar 

  5. McLaughlin S, Shephard J, Wallen E et al (2007) Comparison of the clinical and pathologic staging in patients undergoing radical cystectomy for bladder cancer. Int Braz J Urol 33:25

    Article  PubMed  Google Scholar 

  6. Mehrsai A, Mansoori D, Taheri Mahmoudi M et al (2004) A comparison between clinical and pathologic staging in patients with bladder cancer. Urol J 1:85

    Google Scholar 

  7. Ficarra V, Dalpiaz O, Alrabi N et al (2005) Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU Int 95:786

    Article  PubMed  Google Scholar 

  8. Guzzo TJ, Magheli A, Bivalacqua TJ et al (2009) Pathological upstaging during radical cystectomy is associated with worse recurrence-free survival in patients with bacillus Calmette-Guerin-refractory bladder cancer. Urology 74:1276

    Article  PubMed  Google Scholar 

  9. deVere White RW, Katz MH, Steinberg GD (2009) The case for neoadjuvant chemotherapy and cystectomy for muscle invasive bladder cancer. J Urol 181:1994–1997

    Article  PubMed  Google Scholar 

  10. Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859

    Article  PubMed  CAS  Google Scholar 

  11. Madersbacher S, Hochreiter W, Burkhard F et al (2003) Radical cystectomy for bladder cancer today—a homogeneous series without neoadjuvant therapy. J Clin Oncol 21:690

    Article  PubMed  Google Scholar 

  12. Hotston M, Patel S, Sohail M et al (2006) What is the significance of pT0 at cystectomy? Surg Oncol 15:65

    Article  PubMed  Google Scholar 

  13. Isbarn H, Karakiewicz PI, Shariat SF et al (2009) Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer. J Urol 182:459

    Article  PubMed  Google Scholar 

  14. Svatek RS, Shariat SF, Lasky RE et al (2010) The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res 16:4461

    Article  PubMed  CAS  Google Scholar 

  15. Dimopoulos MA, Moulopoulos LA (1998) Role of adjuvant chemotherapy in the treatment of invasive carcinoma of the urinary bladder. J Clin Oncol 16:1601

    PubMed  CAS  Google Scholar 

  16. Volkmer BG, Kuefer R, Bartsch G Jr et al (2005) Effect of a pT0 cystectomy specimen without neoadjuvant therapy on survival. Cancer 104:2384

    Article  PubMed  Google Scholar 

  17. Thrasher JB, Frazier HA, Robertson JE et al (1994) Does of stage pT0 cystectomy specimen confer a survival advantage in patients with minimally invasive bladder cancer? J Urol 152:393

    PubMed  CAS  Google Scholar 

  18. Herr HW (2001) Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 19:89

    PubMed  CAS  Google Scholar 

  19. Solsona E, Iborra I, Collado A et al (2010) Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. J Urol 184:475

    Article  PubMed  Google Scholar 

  20. Palapattu GS, Shariat SF, Karakiewicz PI et al (2006) Cancer specific outcomes in patients with pT0 disease following radical cystectomy. J Urol 175:1645

    Article  PubMed  Google Scholar 

  21. Yiou R, Patard JJ, Benhard H et al (2002) Outcome of radical cystectomy for bladder cancer according to the disease type at presentation. BJU Int 89:374

    Article  PubMed  CAS  Google Scholar 

  22. Kassouf W, Spiess PE, Brown GA et al (2007) P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol 52:769

    Article  PubMed  Google Scholar 

  23. Smith DC, Mackler NJ, Dunn RL et al (2008) Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. J Urol 180:2384

    Article  PubMed  CAS  Google Scholar 

  24. Sagaster P, Flamm J, Flamm M et al (1996) Neoadjuvant chemotherapy (MVAC) in locally invasive bladder cancer. Eur J Cancer 32A:1320

    Article  PubMed  CAS  Google Scholar 

  25. Duggan B, Williamson K (2004) Molecular markers for predicting recurrence, progression and outcomes of bladder cancer (do the poster boys need new posters?). Curr Opin Urol 14:277

    Article  PubMed  Google Scholar 

  26. Cho KS, Seo HK, Joung JY et al (2009) Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. J Urol 182:2625

    Article  PubMed  Google Scholar 

  27. Kunju LP, You L, Zhang Y et al (2008) Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens. J Urol 180:1928

    Article  PubMed  Google Scholar 

  28. Quek ML, Quinn DI, Daneshmand S et al (2003) Molecular prognostication in bladder cancer–a current perspective. Eur J Cancer 39:1501

    Article  PubMed  CAS  Google Scholar 

  29. Tokunaga H, Shariat SF, Green AE et al (2001) Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens. Int J Radiat Oncol Biol Phys 51:16

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Urology, Mayo Medical School and Mayo Clinic, 200 First Street Southwest, Rochester, MN, 55905, USA

    Matthew K. Tollefson, Stephen A. Boorjian & Igor Frank

  2. Department of Health Sciences Research, Mayo Medical School and Mayo Clinic, Rochester, MN, 55905, USA

    Sara A. Farmer

Authors
  1. Matthew K. Tollefson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen A. Boorjian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sara A. Farmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Igor Frank
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew K. Tollefson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tollefson, M.K., Boorjian, S.A., Farmer, S.A. et al. Downstaging to non-invasive urothelial carcinoma is associated with improved outcome following radical cystectomy for patients with cT2 disease. World J Urol 30, 795–799 (2012). https://doi.org/10.1007/s00345-012-0855-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-012-0855-8

Keywords

Search

Navigation